成都欧林生物科技股份有限公司 董事、高级管理人员及控股股东买卖股票与沟通报备制度（草案） （H 股发行并上市后适用） 第一章 总则 第一条 为加强对公司董事、高级管理人员（以下简称"董高"）及控股股东 持有及买卖本公司股票的管理，进一步明确办理程序，根据《中华人民共和国公 司法》《中华人民共和国证券法》《上市公司董事和高级管理人员所持本公司股 份及其变动管理规则》《上市公司股东减持股份管理暂行办法（2025 年修订）》 《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人 员减持股份》《香港联合交易所有限公司证券上市规则》（以下简称"《香港上 市规则》"，包括但不限于《上市发行人董事进行证券交易的标准守则》和《企 业管治守则》，其中"香港联合交易所有限公司"以下简称"香港联交所"）、 《证券及期货条例》等相关法律法规、公司股票上市地证券监管规则和《公司章 程》的有关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司董事、高级管理人员及控股股东所持本公司股份 及其变动的管理。 第三条 董事、高级管理人员及控股股东开立多个证券账户的，对各证券账 户的持股合并计算；董事、高级管理人 ...

欧林生物公告，第三季度营收为2.01亿元，同比增长25.38%；净利润为3428.29万元，同比增长7.22%。 前三季度营收为5.07亿元，同比增长31.11%；净利润为4747.98万元，同比增长1,079.36%。 ...

Core Viewpoint - The domestic vaccine industry is experiencing significant pressure due to economic downturns, declining birth rates, reduced vaccination willingness, and intensified market competition, leading to frequent executive changes among companies [1][3]. Group 1: Executive Changes - Sun Wanfeng has resigned from his position as employee representative director and vice president of Baike Bio, but will continue as assistant to the chairman [1]. - There are rumors of changes in the management of Kangtai Bio, but the company has confirmed that Vice President Yu Bing remains in his position [1]. - Frequent executive turnover is noted in the domestic vaccine industry, with several companies undergoing leadership changes since late 2024 [3]. Group 2: Financial Performance - In the first half of 2025, only 5 out of 10 listed vaccine companies in A-shares reported revenue growth, with only 3 achieving positive net profit growth [3]. - Baike Bio reported a revenue of 284.9 million yuan with a net loss of 73.57 million yuan, marking a year-on-year revenue decline of 53.93% and a net profit decline of 153.47% [4]. - Kangtai Bio's revenue was 1.392 billion yuan with a net profit of 37.53 million yuan, showing a revenue growth of 15.81% but a significant net profit decline of 77.30% [4]. Group 3: Market Competition - The HPV vaccine market is experiencing aggressive price competition, with prices for the bivalent HPV vaccine dropping below 100 yuan, and the lowest price recorded at 27.5 yuan per dose [5]. - The flu vaccine market is also seeing price reductions, with prices for quadrivalent flu vaccines dropping from 128 yuan to 88 yuan per dose [6]. - The pneumococcal vaccine market is highly competitive, with Pfizer withdrawing from the market due to intense competition from domestic products [6]. Group 4: Growth Opportunities - Despite the challenges, there are structural growth opportunities in the vaccine market, exemplified by Olin Bio's adsorbed tetanus vaccine, which achieved a revenue growth of 35.17% in the first half of 2025 [7].

Core Viewpoint - The company, Olin Bio (688319.SH), is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [1] Group 1: H-Share Listing Plans - Olin Bio is in discussions with relevant intermediaries regarding the H-share listing, with specific details yet to be determined [1] - The H-share listing will require approval from the company's board, shareholders, and various regulatory bodies including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1] Group 2: Previous A-Share Issuance Attempt - On August 31, Olin Bio announced the termination of its plan to issue A-shares through a simplified procedure due to current market conditions and company strategy [2] - The previous A-share issuance aimed to raise up to 300 million RMB, with a proposed subscription amount of 12,529.29 million RMB for specific investors [2] Group 3: Shareholder Changes - The controlling shareholder, Shanghai Wushan Biotechnology Co., Ltd., reduced its stake by 4.4028 million shares, realizing approximately 119.98 million RMB from the sale [4] - Following the reduction, the shareholding of Shanghai Wushan and its concerted parties decreased from 29.00% to 27.92% of the total shares [4] Group 4: Financial Performance - Olin Bio's revenue from 2021 to 2024 was reported as 487 million RMB, 548 million RMB, 496 million RMB, and 589 million RMB respectively, with net profits of 108 million RMB, 26.58 million RMB, 17.56 million RMB, and 20.76 million RMB [6]

据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日，注册资本40593.36万人民 币。（数据宝） 10月22日欧林生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 15.00 | 315.00 | 21.00 | -9.33 | 瑞银证券有限责任公司上 | 广发证券股份有限公司成 | | | | | | 海花园石桥路证券营业部 | 都麓山大道证券营业部 | 欧林生物10月22日大宗交易平台出现一笔成交，成交量15.00万股，成交金额315.00万元，大宗交易成交 价为21.00元，相对今日收盘价折价9.33%。该笔交易的买方营业部为瑞银证券有限责任公司上海花园石 桥路证券营业部，卖方营业部为广发证券股份有限公司成都麓山大道证券营业部。 进一步统计，近3个月内该股累计发生18笔大宗交易，合计成交金额为9671.13万元。 证券时报·数据宝统计显 ...

| No 224 080 yer 111 10% | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | 证券简称 | 交易日期 | 卖出营业部 | 是否为专场 | 证券代码 | | | | | 發開工資表重量 | 全部委員會出契盟 | 025-10-22 | 688319 | 欧林生物 | 315 | 15 | 21 | 150 | 10月22日，欧林生物大宗交易成交15万股，成交额315万元，占当日总成交额的2.63%，成交价21元， 较市场收盘价23.16元折价9.33%。 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-050 成都欧林生物科技股份有限公司关于收购 控股子公司少数股东股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、交易概述 （一）本次交易进展情况 2025 年 9 月 9 日，成都生物城一号股权投资基金合伙企业（有限合伙）（以 下简称"一号基金"）、成都生物城菁创股权投资基金合伙企业（有限合伙）（以 下简称"菁创基金"）通过西南联合产权交易所公开挂牌转让一号基金持有的成 都新诺明生物科技有限公司（以下简称"新诺明生物"）8.1081%的股权以及菁创 基金持有的新诺明生物 6.8919%的股权，挂牌转让底价合计为 3,877.2763 万元。 2025 年 10 月 9 日，公司向西南联合产权交易所提交了申请受让资料，并于 2025 年 10 月 14 日收到西南联合产权交易所出具的《关于意向投资资格确认的告 知函》以及《关于成交相关事项的告知函》，确认公司成为新诺明生物 15%股权的 受让方，公司按要求在规定时间内向西南联合产权交易所指定的 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.51% on October 17, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers included: - Hualan Weishen (301207) with a closing price of 19.49, up 9.80% and a trading volume of 182,600 shares, totaling 349 million yuan [1] - ST Weiming (002581) closed at 7.65, up 4.37% with a trading volume of 125,000 shares, totaling 9.524 million yuan [1] - Major decliners included: - Olin Bio (688319) closed at 22.91, down 6.45% with a trading volume of 68,700 shares, totaling 161 million yuan [2] - Kanhua Bio (300841) closed at 75.29, down 4.08% with a trading volume of 33,800 shares, totaling 260 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 581 million yuan from institutional investors, while retail investors contributed a net inflow of 444 million yuan [2] - The detailed capital flow for selected stocks showed: - Junshi Bio (688180) had a net inflow of 63.85 million yuan from institutional investors, but a net outflow of 61.01 million yuan from retail investors [3] - Hualan Weishen (301207) saw a net inflow of 18.07 million yuan from institutional investors, with a net outflow of 20.09 million yuan from retail investors [3]

Core Viewpoint - On October 15, 2023, Olin Bio conducted two block trades totaling 1,092,200 shares, amounting to 20.93 million yuan, with a transaction price of 19.16 yuan, reflecting a discount of 23.24% compared to the closing price of the day [1] Trading Activity - The total trading volume for the two block trades was 1,092,200 shares, with a total transaction value of 20.93 million yuan [1] - The transaction price of 19.16 yuan represented a discount of 23.24% relative to the closing price of 24.96 yuan on the same day [1] - In the last three months, Olin Bio has recorded 17 block trades with a cumulative transaction value of 93.56 million yuan [1] Market Performance - Olin Bio's stock closed at 24.96 yuan, showing an increase of 4.22% on the day, with a turnover rate of 1.62% and a total trading volume of 163 million yuan [1] - Over the past five days, the stock has declined by 8.24%, with a net outflow of funds totaling 8.73 million yuan [1] Financing Data - The latest margin financing balance for Olin Bio is 318 million yuan, which has increased by 5.37 million yuan over the past five days, representing a growth rate of 1.72% [1] Company Background - Chengdu Olin Bio Technology Co., Ltd. was established on December 11, 2009, with a registered capital of 4,059.336 million yuan [1]

10月15日，欧林生物大宗交易成交109.22万股，成交额2092.66万元，占当日总成交额的11.4%，成交价 19.16元，较市场收盘价24.96元折价23.24%。 | 交易日期 | 证券简称 | 证券代码 | | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | 类出管业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-15 | 欧林生物 | 612889 | 19.16 | 1067.06 | 55.69 委員會委員會議 | 是第一次的第四 | 客 | | 2025-10-15 | 欧林生物 | 688319 | 19.16 | 1025.6 | 53.53 委員會委員會議 | ្នក់​មួយ​និង​ដុង | Ka | ...